» Articles » PMID: 11296695

Nonalcoholic Steatohepatitis: Definition and Pathology

Overview
Journal Semin Liver Dis
Publisher Thieme
Specialty Gastroenterology
Date 2001 Apr 12
PMID 11296695
Citations 251
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis (NASH) is a significant form of chronic liver disease in adults and children. The natural history of NASH ranges from indolent to end-stage liver disease. Current studies are focusing on identification of histologic and/or clinical markers of progression. NASH may be an underlying cause of cryptogenic cirrhosis, and the lesions of NASH may recur in allograft livers. An expanding array of clinical conditions and pathogenetic mechanisms have been identified, but many cases remain "idiopathic"; lack of significant alcohol use is, by definition, common to all cases. Neither clinical evaluation nor laboratory values can ensure either the diagnosis or the exclusion of NASH, and liver biopsy interpretation continues to be considered the "gold standard" for diagnosis. The lesions in NASH are similar but not identical to those of alcoholic steatohepatitis; exact, specific histologic criteria for the diagnosis are currently under discussion. The lesions most commonly accepted for NASH include steatosis, hepatocyte ballooning degeneration, mild diffuse lobular mixed acute and chronic inflammation, and perivenular, perisinusoidal collagen deposition. Zone 3 accentuation may be detected. Mallory's hyaline, vacuolated nuclei in periportal hepatocytes, lobular lipogranulomas, and PAS-diastase-resistant Kupffer cells are common. In biopsy specimens from children, portal inflammation may be more prominent than in adults. Progression of fibrosis may result in bridging septa and cirrhosis. The lesions of steatohepatitis may be noted concurrently with other forms of chronic liver disease. A histological "grading and staging" system has been developed to reflect the unique features of steatohepatitis, gradations of severity and fibrosis, and to promote uniform reporting of the histopathology.

Citing Articles

Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review.

Arteaga I, Chacon C, Martinez-Escude A, Rojano I, Diez-Fadrique G, Carmona-Cervello M Diagnostics (Basel). 2025; 15(3).

PMID: 39941229 PMC: 11816681. DOI: 10.3390/diagnostics15030299.


Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective.

Baffy G, Portincasa P Metabolites. 2024; 14(6).

PMID: 38921459 PMC: 11205793. DOI: 10.3390/metabo14060324.


Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human.

Tsouka S, Kumar P, Seubnooch P, Freiburghaus K, St-Pierre M, Dufour J Commun Med (Lond). 2024; 4(1):39.

PMID: 38443644 PMC: 10914730. DOI: 10.1038/s43856-024-00465-3.


Sotagliflozin attenuates liver-associated disorders in cystic fibrosis rabbits.

Liang X, Hou X, Bouhamdan M, Sun Y, Song Z, Rajagopalan C JCI Insight. 2024; 9(6).

PMID: 38358827 PMC: 10972622. DOI: 10.1172/jci.insight.165826.


Digital pathology for nonalcoholic steatohepatitis assessment.

Sanyal A, Jha P, Kleiner D Nat Rev Gastroenterol Hepatol. 2023; 21(1):57-69.

PMID: 37789057 DOI: 10.1038/s41575-023-00843-7.